Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Surgery in Treating Children With Neuroblastoma
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated:  2/29/2016
Madigan Army Medical Center
mi
from
Tacoma, WA
Surgery in Treating Children With Neuroblastoma
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Madigan Army Medical Center
mi
from
Tacoma, WA
Click here to add this to my saved trials
Surgery in Treating Children With Neuroblastoma
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated:  2/29/2016
West Virginia University Robert C. Byrd Health Sciences Center, Charleston Division
mi
from
Charleston, WV
Surgery in Treating Children With Neuroblastoma
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
West Virginia University Robert C. Byrd Health Sciences Center, Charleston Division
mi
from
Charleston, WV
Click here to add this to my saved trials
Surgery in Treating Children With Neuroblastoma
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated:  2/29/2016
Cabell Huntington Hospital
mi
from
Huntington, WV
Surgery in Treating Children With Neuroblastoma
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Cabell Huntington Hospital
mi
from
Huntington, WV
Click here to add this to my saved trials
Surgery in Treating Children With Neuroblastoma
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated:  2/29/2016
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
Surgery in Treating Children With Neuroblastoma
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
West Virginia University Hospitals Inc.
mi
from
Morgantown, WV
Click here to add this to my saved trials
Surgery in Treating Children With Neuroblastoma
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated:  2/29/2016
Bellin Memorial Hospital
mi
from
Green Bay, WI
Surgery in Treating Children With Neuroblastoma
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Bellin Memorial Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Surgery in Treating Children With Neuroblastoma
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated:  2/29/2016
CCOP - St. Vincent Hospital Cancer Center, Green Bay
mi
from
Green Bay, WI
Surgery in Treating Children With Neuroblastoma
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
CCOP - St. Vincent Hospital Cancer Center, Green Bay
mi
from
Green Bay, WI
Click here to add this to my saved trials
Surgery in Treating Children With Neuroblastoma
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated:  2/29/2016
St. Vincent Hospital
mi
from
Green Bay, WI
Surgery in Treating Children With Neuroblastoma
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
St. Vincent Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Surgery in Treating Children With Neuroblastoma
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated:  2/29/2016
Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center
mi
from
La Crosse, WI
Surgery in Treating Children With Neuroblastoma
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center
mi
from
La Crosse, WI
Click here to add this to my saved trials
Surgery in Treating Children With Neuroblastoma
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated:  2/29/2016
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Surgery in Treating Children With Neuroblastoma
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
University of Wisconsin Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Surgery in Treating Children With Neuroblastoma
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated:  2/29/2016
Marshfield Clinic
mi
from
Marshfield, WI
Surgery in Treating Children With Neuroblastoma
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Marshfield Clinic
mi
from
Marshfield, WI
Click here to add this to my saved trials
Surgery in Treating Children With Neuroblastoma
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated:  2/29/2016
CCOP - Marshfield Clinic Research Foundation
mi
from
Marshfield, WI
Surgery in Treating Children With Neuroblastoma
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
CCOP - Marshfield Clinic Research Foundation
mi
from
Marshfield, WI
Click here to add this to my saved trials
Surgery in Treating Children With Neuroblastoma
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated:  2/29/2016
Midwest Children's Cancer Center
mi
from
Milwaukee, WI
Surgery in Treating Children With Neuroblastoma
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Midwest Children's Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Surgery in Treating Children With Neuroblastoma
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated:  2/29/2016
Sydney Children's Hospital
mi
from
Randwick,
Surgery in Treating Children With Neuroblastoma
Primary Surgical Therapy for Biologically Defined Low-Risk Neuroblastoma: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study
Status: Enrolling
Updated: 2/29/2016
Sydney Children's Hospital
mi
from
Randwick,
Click here to add this to my saved trials
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Palo Alto, CA
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Aurora, CO
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Washington,
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Orlando, FL
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Chicago, IL
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Baltimore, MD
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Boston, MA
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
New York, NY
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Houston, TX
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated:  3/1/2016
Clinical Research Facility
mi
from
Seattle, WA
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated:  3/1/2016
mi
from
Toronto,
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System
Status: Enrolling
Updated: 3/1/2016
mi
from
Toronto,
Click here to add this to my saved trials
Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas
Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas
Status: Enrolling
Updated:  3/2/2016
Johns Hopkins Bayview Medical Center
mi
from
Baltimore, MD
Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas
Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas
Status: Enrolling
Updated: 3/2/2016
Johns Hopkins Bayview Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas
Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas
Status: Enrolling
Updated:  3/2/2016
Johns Hopkins Hospital
mi
from
Baltimore, MD
Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas
Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas
Status: Enrolling
Updated: 3/2/2016
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas
A Phase 1b Study of AdV-tk + Valacyclovir Gene Therapy in Combination With Standard Radiation Therapy for Malignant Gliomas
Status: Enrolling
Updated:  3/2/2016
The Ohio State University Medical Center, Dept Neurosurgery
mi
from
Columbus, OH
Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas
A Phase 1b Study of AdV-tk + Valacyclovir Gene Therapy in Combination With Standard Radiation Therapy for Malignant Gliomas
Status: Enrolling
Updated: 3/2/2016
The Ohio State University Medical Center, Dept Neurosurgery
mi
from
Columbus, OH
Click here to add this to my saved trials
Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas
A Phase 1b Study of AdV-tk + Valacyclovir Gene Therapy in Combination With Standard Radiation Therapy for Malignant Gliomas
Status: Enrolling
Updated:  3/2/2016
The Methodist Hosptial
mi
from
Houston, TX
Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas
A Phase 1b Study of AdV-tk + Valacyclovir Gene Therapy in Combination With Standard Radiation Therapy for Malignant Gliomas
Status: Enrolling
Updated: 3/2/2016
The Methodist Hosptial
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of IMC-A12 in Islet Cell Cancer
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated:  3/3/2016
ImClone Investigational Site
mi
from
Los Angeles, CA
A Study of IMC-A12 in Islet Cell Cancer
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated: 3/3/2016
ImClone Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of IMC-A12 in Islet Cell Cancer
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated:  3/3/2016
ImClone Investigational Site
mi
from
Aurora, CO
A Study of IMC-A12 in Islet Cell Cancer
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated: 3/3/2016
ImClone Investigational Site
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of IMC-A12 in Islet Cell Cancer
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated:  3/3/2016
ImClone Investigational Site
mi
from
Atlanta, GA
A Study of IMC-A12 in Islet Cell Cancer
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated: 3/3/2016
ImClone Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of IMC-A12 in Islet Cell Cancer
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated:  3/3/2016
ImClone Investigational Site
mi
from
Indianapolis, IN
A Study of IMC-A12 in Islet Cell Cancer
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated: 3/3/2016
ImClone Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of IMC-A12 in Islet Cell Cancer
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated:  3/3/2016
ImClone Investigational Site
mi
from
Kenner, LA
A Study of IMC-A12 in Islet Cell Cancer
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated: 3/3/2016
ImClone Investigational Site
mi
from
Kenner, LA
Click here to add this to my saved trials
A Study of IMC-A12 in Islet Cell Cancer
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated:  3/3/2016
ImClone Investigational Site
mi
from
Columbus, OH
A Study of IMC-A12 in Islet Cell Cancer
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated: 3/3/2016
ImClone Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of IMC-A12 in Islet Cell Cancer
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated:  3/3/2016
ImClone Investigational Site
mi
from
Providence, RI
A Study of IMC-A12 in Islet Cell Cancer
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated: 3/3/2016
ImClone Investigational Site
mi
from
Providence, RI
Click here to add this to my saved trials
A Study of IMC-A12 in Islet Cell Cancer
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated:  3/3/2016
ImClone Investigational Site
mi
from
Nashville, TN
A Study of IMC-A12 in Islet Cell Cancer
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated: 3/3/2016
ImClone Investigational Site
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of IMC-A12 in Islet Cell Cancer
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated:  3/3/2016
ImClone Investigational Site
mi
from
Dallas, TX
A Study of IMC-A12 in Islet Cell Cancer
A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma
Status: Enrolling
Updated: 3/3/2016
ImClone Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated:  3/4/2016
Duke Univ Med Ctr
mi
from
Durham, NC
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated:  3/4/2016
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Click here to add this to my saved trials
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated:  3/4/2016
Childrens National Medical Center
mi
from
Washington,
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated:  3/4/2016
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated:  3/4/2016
Dana-Farber / Harvard Cancer Center
mi
from
Boston, MA
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
Dana-Farber / Harvard Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated:  3/4/2016
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated:  3/4/2016
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated:  3/4/2016
Pediatric Brain Tumor Consortium
mi
from
Memphis, TN
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
Pediatric Brain Tumor Consortium
mi
from
Memphis, TN
Click here to add this to my saved trials
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated:  3/4/2016
St. Jude Children's Research Hospital
mi
from
Memphis, TN
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated:  3/4/2016
Texas Children's Hospital
mi
from
Houston, TX
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated:  3/4/2016
Seattle Children's Hospital
mi
from
Seattle, WA
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
A Phase I Clinical Trial of AZD2171 in Children With Recurrent or Progressive Central Nervous System (CNS) Tumors
Status: Enrolling
Updated: 3/4/2016
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials